Octapharma Group Delivered Strong Growth in Both Sales and Operating Income In 2019

▴ Octapharma Group Delivered Strong Growth in Both Sales and Operating Income In 2019
Octapharma has seven R&D sites and six state-of-the-art manufacturing facilities in Austria, France, Germany, Mexico and Sweden, in addition to more than 120 plasma centres across Europe and the US.

The Octapharma Group has delivered a strong performance in 2019. Sales of €2.2 billion represent an increase of €417 million (23.2%) compared to 2018. Furthermore, operating income increased by €78.6 million (22.7%) compared with 2018, to €424 million.

Gross profit in 2019 was €783 million, which is €152 million more than 2018. Despite continued investments in plasma collection and production capacities to fulfil the growing global demand for our products, gross margin increased by 0.3% to 35.4%.

Significant investments were made for the Group’s future prosperity in R&D and into the extension of plasma collection and production capacities. Important milestones in the expansion and utilisation of the plasma and recombinant product portfolio became a reality during the last 12 months. To ensure each litre of plasma is optimally used, the Group will continue to enter new markets and expand its portfolio with innovative new products and services.

Highlights of the performance

Reported revenues of €2.2 billion represent an increase of €417 million (23.2%) on 2018 Operating income of €424 million represents an increase of €78.6 million (22.7%) on 2018 All products performed well, but highlights are the year-on-year growth of the Group’s immunoglobulin product portfolio, as well as Nuwiq, albunorm and fibryga.

Commenting on the Group’s results, Octapharma CEO and Chairman Wolfgang Marguerre said: “Octapharma delivered an exceptionally strong result in 2019. We achieved good growth in all three of our therapeutic areas. We continued to invest significantly in R&D to fund the discovery and development of new life-changing treatments, as well as in our plasma collection capacities to ensure the future supplies of our life-saving products for patients. Our new subcutaneous immunoglobulin (SCIG), cutaquig, received approval in Europe following approvals in 2018 in the USA and Canada. The European Medicines Agency (EMA) approved an updated label for our recombinant factor VIII (rFVIII), Nuwiq to include data on effective bleed protection with twice weekly dosing using personalised prophylaxis. Fibryga received European approval to treat acquired fibrinogen deficiencies, extending the earlier approval for use in patients with congenital fibrinogen deficiency. These approvals bring substantial benefits to patients as well as physicians. Based on our existing product portfolio and our development pipeline, Octapharma is well positioned to continue to perform strongly in the coming years.”

Tags : #Octapharmagroup #Stronggrowth #Sales #Operatingincome

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Surviving Against the Odds: Steven Spinale's Journey After an Ingrown Hair Turns DeadlyMarch 29, 2024
10 reasons why media research and Planning are essential in Healthcare marketingMarch 29, 2024
The Surprising Link Between Sleep and Age Perception: What You Need to KnowMarch 29, 2024
The Dark Side of Beauty: Kidney Damage from Hair Straightening TreatmentsMarch 29, 2024
The Dark Side of Beauty: Kidney Damage from Hair Straightening TreatmentsMarch 29, 2024
Avance Clinical at World Vaccine Congress to Share Latest Vaccine Clinical Trial News Including an HIV-1 StudyMarch 29, 2024
Sexual wellness superstore, Love Depot launches digital campaign to deliver every desireMarch 28, 2024
Recharge Your Life: Simple Ways to Boost Your Physical and Mental EnergyMarch 28, 2024
The Neurological Toll of Common Household Chemicals: Insights from Recent ResearchMarch 28, 2024
The Aging Puzzle: Decoding the Mechanisms of AgingMarch 28, 2024
The Double-Edged Sword of Kala-azar Treatment: Shedding Light on Eye ComplicationsMarch 28, 2024
FTCCI Launches Industry-Academia Connect to improve the employability of Engineering Graduates and address the growing demand for Talent in Emerging TechMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
2nd Edition of IIFL JITO Ahimsa Run for peace & for non-violence to be held on 31st MarchMarch 27, 2024
Brij Hotels Announced 4 Million in Series A Funding March 27, 2024
Combatting Childhood Sedentariness: The Key to Preventing Premature Vascular DamageMarch 27, 2024
Crucial Findings: Unlocking Paths to Combat Ebola's DevastationMarch 27, 2024
Guarding Against Disease: The Crucial Role of Oral Hygiene in Preventive HealthcareMarch 27, 2024
Sanofi & Cipla announce exclusive distribution partnership to expand reach of CNS portfolio in IndiaMarch 26, 2024